Ardenermin
Alternative Names: B-Lymphocyte stimulator; BAFF; BLyS; TALL-1; THANK; TL 7; TNFSBF 13B; TNSF 20; zTNF 4Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Human Genome Sciences
- Developer Dyax Corp.; Human Genome Sciences
- Class
- Mechanism of Action B cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Common variable immunodeficiency; Selective immunoglobulin A deficiency
Most Recent Events
- 31 Dec 2004 Discontinued - Phase-I for Common Variable Immunodeficiency in USA (unspecified route)
- 31 Dec 2004 Discontinued - Phase-I for Selective immunoglobulin A deficiency in USA (unspecified route)
- 30 Apr 2004 Suspended - Phase-I for Common Variable Immunodeficiency in USA (unspecified route)